Tenaya Therapeutics Inc (TNYA) Stock Price, Quote & News

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone de...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 825 6990

Website: www.tenayatherapeutics.com

Address:

171 Oyster Point Boulevard, Suite 500, South San Francisco, United States

Paulfrench Aug. 6 at 12:08 PM

$TNYA A hidden bullish divergence has appeared recently, it is not a complete insurance but on this graph the divergences have always produced a short term effect whether they are bearish or bullish...it is one more clue to tell us that the price will rise

1 · Reply

Paulfrench Aug. 5 at 10:54 AM

Hello $TNYA Contrary to what I said, the price came to seek the level of the fair value gap (option #2 post below) 🤷‍♂️ ... level which is generally strongly defended by buyers, Yesterday's candle was rather a beautiful candle, even if it needs to be confirmed today. Indeed the day opens with a slight bearish gap (#1) signifying a slight pressure from the sellers but after having touched the lowest of the day before, the 50MA and the fair value GAP (#2) the price arrives in an area where the sellers no longer have strength and the price rises without effort to finish above the highest of the day before (#3) In my opinion it is a strong rebound signal (however a quick return to $0.633 remains possible today), now we need to find a clearly bullish candle with increasing volume to confirm the change of trend.

2 · Reply

TWITLIEDETECTOR Aug. 3 at 6:45 PM

$TNYA other than posts from the company or factual type information, dont believe any post you read on Stocktwits especially right before earnings. You'll get the pumpers or the negative people.... never buy into the buy ratings from the analysts. They are typically right about 33% of the time if that.

1 · Reply

Cel55 Aug. 3 at 10:04 AM

The August 6 earnings report will be a critical turning point for TNYA, determining not just its past performance but also its ability to remain listed and regain investor confidence. If the loss comes in around –$0.16 and cash reserves exceed $80 million, it would signal that the burn rate is under control, potentially driving the stock toward $0.75 and organically testing the $1 mark. Conversely, a deeper loss (above –$0.22) combined with weak cash reserves could reignite concerns about a reverse split and dilution, putting downward pressure on the stock below $0.60. $TNYA

2 · Reply

Crazyrussiankid Aug. 1 at 3:28 PM

$TNYA 🚨shares on discount 🚨I repeat shares on discount 🔔

0 · Reply

Raumerica Aug. 1 at 5:07 AM

$TNYA This will give the company another 2 quarter runway until the end of 2026 or into the 1st quarter of 2027.

1 · Reply

Raumerica Jul. 31 at 10:12 PM

$TNYA Now that I have researched, and have a crystal clear understanding. Here is my take. TNYA is going to dilute 37.5 million more share in June 2026. But this time, the company will receive $52.5 million. This Is contingent upon the share price being near or above $1.40. This is a date to prepare for and act accordingly.

2 · Reply

Raumerica Jul. 31 at 10:03 PM

$TNYA So pretty much a nothing burger. Sorry about that.

0 · Reply

VolcanicTrades Jul. 31 at 9:56 PM

$FIG congrats guys. Beautiful ipo day $GLMD $TNYA $SPY

0 · Reply

Raumerica Jul. 31 at 9:50 PM

$TNYA I still like it. Dilute all u want at double my cost avg.

1 · Reply

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

May 15, 2025, 9:00 PM EDT - 2 months ago

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 13, 2025, 8:30 AM EDT - 3 months ago

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Apr 24, 2025, 2:07 PM EDT - 3 months ago

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Mar 31, 2025, 10:00 AM EDT - 4 months ago

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Mar 24, 2025, 8:30 AM EDT - 4 months ago

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Mar 19, 2025, 8:30 AM EDT - 5 months ago

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Mar 10, 2025, 4:05 PM EDT - 5 months ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 11:19 PM EST - 5 months ago

Tenaya Therapeutics Announces Pricing of Public Offering

Mar 3, 2025, 4:10 PM EST - 5 months ago

Tenaya Therapeutics Announces Proposed Public Offering

Mar 3, 2025, 8:00 AM EST - 5 months ago

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Feb 3, 2025, 8:30 AM EST - 6 months ago

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Jan 13, 2025, 9:16 AM EST - 7 months ago

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Dec 16, 2024, 4:30 PM EST - 8 months ago

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Nov 6, 2024, 4:05 PM EST - 9 months ago

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 17, 2024, 4:30 PM EDT - 10 months ago

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

Jun 27, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics Announces Research Leadership Updates

Jun 18, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

May 14, 2024, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Feb 26, 2024, 8:30 AM EST - 1 year ago

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Feb 8, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Announces Pricing of Underwritten Offering

Jan 3, 2024, 8:30 AM EST - 1 year ago

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:30 PM EST - 1 year ago

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

Oct 26, 2023, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Oct 9, 2023, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

Oct 2, 2023, 5:30 PM EDT - 2 years ago

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Sep 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

Sep 21, 2023, 5:11 AM EDT - 2 years ago

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

SCLX SGHT TSBX

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:19 PM EDT - 2 years ago

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 7:50 AM EDT - 2 years ago

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

NKTX

Apr 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 8, 2023, 4:01 PM EST - 2 years ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 7, 2023, 5:17 PM EST - 2 years ago

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

Dec 7, 2022, 4:30 PM EST - 2 years ago

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

Nov 28, 2022, 8:30 AM EST - 2 years ago

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

Nov 23, 2022, 9:00 AM EST - 2 years ago

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

Nov 21, 2022, 5:45 PM EST - 2 years ago

Tenaya Therapeutics Announces Closing of Public Offering

Oct 4, 2022, 8:30 AM EDT - 3 years ago

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress

Sep 29, 2022, 7:45 AM EDT - 3 years ago

Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

Aug 10, 2022, 4:01 PM EDT - 3 years ago

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Jul 6, 2022, 2:00 PM EDT - 3 years ago

Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure

Jun 16, 2022, 8:00 AM EDT - 3 years ago

Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics

May 20, 2022, 8:30 AM EDT - 3 years ago

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

Paulfrench Aug. 6 at 12:08 PM

1 · Reply

Paulfrench Aug. 5 at 10:54 AM

2 · Reply

TWITLIEDETECTOR Aug. 3 at 6:45 PM

1 · Reply

Cel55 Aug. 3 at 10:04 AM

2 · Reply

Crazyrussiankid Aug. 1 at 3:28 PM

$TNYA 🚨shares on discount 🚨I repeat shares on discount 🔔

0 · Reply

Raumerica Aug. 1 at 5:07 AM

$TNYA This will give the company another 2 quarter runway until the end of 2026 or into the 1st quarter of 2027.

1 · Reply

Raumerica Jul. 31 at 10:12 PM

2 · Reply

Raumerica Jul. 31 at 10:03 PM

$TNYA So pretty much a nothing burger. Sorry about that.

0 · Reply

VolcanicTrades Jul. 31 at 9:56 PM

$FIG congrats guys. Beautiful ipo day $GLMD $TNYA $SPY

0 · Reply

Raumerica Jul. 31 at 9:50 PM

$TNYA I still like it. Dilute all u want at double my cost avg.

1 · Reply

Raumerica Jul. 31 at 9:49 PM

$TNYA Upon rereading, they didn't need to pay upfront but will be giving TNYA $5 million cash on June 30th, 2026. I stand corrected about the upfront fee. Sorry for misrembering

0 · Reply

Raumerica Jul. 31 at 9:40 PM

$TNYA Yes, 1/2 warrants not even dilutive. Exercisable June 2026. But $1.40 strike. I bought some AH and am loading up tomorrow too

0 · Reply

Raumerica Jul. 31 at 9:28 PM

$TNYA 3.6 million 1/2 warrants purchased by Empery at $3 million buck cost. $1.40 strike just to break even on the warrants

0 · Reply

TWITLIEDETECTOR Jul. 31 at 9:10 PM

$TNYA many baby bios getting a whoopin before earnings. Don’t panic

1 · Reply

Raumerica Jul. 31 at 9:08 PM

$TNYA I gonna buy the shit outta this tomorrow.

0 · Reply

Raumerica Jul. 31 at 8:59 PM

$TNYA Good luck shorties... ROTFLMAO... The tute spent 3 million betting it will go much higher than $1.40

0 · Reply

Raumerica Jul. 31 at 8:56 PM

$TNYA Awesome... This tute exercised 3.6 million of the 1/2 warrants at 70 cents. 1.40 strike price!!! I bought a shit load today. Gimme more...

0 · Reply

Apiker Jul. 31 at 8:42 PM

$TNYA weekly chart saying, we’re nearing the bottom. But who knows with this 💩

0 · Reply

Cel55 Jul. 31 at 8:32 PM

@Paulfrench $TNYA "I really value your thoughts, please share your analysis."

0 · Reply

Zeyyy Jul. 31 at 5:51 PM

$TNYA this stock is complete and total bullshit. For months waiting for a hope but nope just wasted time and money. Do you think should just get rid of it or keep it a little longer?

2 · Reply

Crazyrussiankid Jul. 31 at 3:26 PM

$TNYA needs a lucky charm

0 · Reply

King_of_Bio Jul. 31 at 3:00 PM

$TNYA We need to hit $1 by Oct 13th to avoid a split or delisting. There will be dilution, no getting around it, and the cash runway is very tight. Let's see what the board has in store for us for the rest of the year. Unless you're avg down, I wouldn't buy till the dust settles in Oct. Not financial advice!

1 · Reply

Market Cap	112.78M
Revenue (ttm)	0.00
Net Income (ttm)	-111.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	689,631
Avg Vol	2,478,886
Day's Range	N/A - N/A
Shares Out	162.67M
Stochastic %K	21%
Beta	3.01
Analysts	Strong Sell
Price Target	$10.14